Quest Diagnostics (DGX) Stock Price, Fundamentals & Analysis

What DGX does

Quest Diagnostics (DGX) is a US stock in the Healthcare sector, specifically the Diagnostics & Research industry, headquartered in Secaucus, United States. The company provides diagnostic testing and services across the United States, offering routine, non-routine, and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It operates under the Quest Diagnostics brand as well as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, serving physicians, hospitals, patients, health plans, government agencies, employers, retailers, pharmaceutical companies, insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, and mobile health professionals.

Key numbers explained

• 233 USD is the current share price, the amount you would pay for one share of DGX today.
• The trailing P/E ratio of 25.8 shows how much investors pay per dollar of the company's last 12 months of earnings; a higher number can mean the market expects strong future growth.
• The forward P/E ratio of 19.3 uses expected future earnings, which can make the stock look cheaper if those earnings grow.
• Earnings per share, trailing 12 months of 9.04 USD is the portion of net income attributable to each share over the last year.
• The dividend yield of 1.47% is the annual dividend payment expressed as a percentage of the current share price, useful for income-focused investors.
• The ex-dividend date of Oct 6, 2026 is the cutoff: you must own the stock before this date to receive the next dividend.
• 26% of earnings paid out as dividends indicates the company returns roughly a quarter of its profit to shareholders, keeping the rest for reinvestment or debt reduction.
• Beta of 0.55 suggests DGX is less volatile than the overall market; it tends to move about half as much as the broader market in either direction.
• The 52-week price range of 171.18 – 248.84 shows the lowest and highest traded prices over the past year, while the 25.7% price change over that period reflects the one-year return.
• Revenue, trailing 12 months of 11.56 mld. USD and revenue growth, year over year of 10.2% describe the top-line scale and growth rate.
• Profit margin of 9.2% and operating margin of 15.2% measure how much of each revenue dollar turns into net profit and operating profit, respectively.
• Return on equity of 14.6% indicates how effectively the company generates profit from shareholders' equity.
• The debt-to-equity ratio of 81.1% shows the proportion of debt relative to equity used to finance the business.
• Price-to-book of 3.41 compares the market price to the company's book value per share.
• The next earnings date, Oct 22, 2026, is when the company is scheduled to report its latest financial results.

Recent news

• Headlines note that Quest Diagnostics (DGX) could be trading below fair value after the Apple Health launch and also following Medicare payment cut concerns.
• Other stories include a general market update mentioning the Dow and Apple, a scheduled third quarter earnings release on October 22, 2026, and a drop in DGX stock on a given day.
• A separate headline highlights the NICU genetic testing market size and trends for the 2026–2036 period, which relates to the broader diagnostics landscape.

What to watch

As a Healthcare stock, DGX can be sensitive to changes in Medicare and Medicaid reimbursement rates, regulatory actions, and broader health policy shifts. Investors often compare it with peers such as DaVita (DVA), Universal Health Services (UHS), McKesson Corporation (MCK), Bio-Techne (TECH), Insulet Corporation (PODD), Boston Scientific (BSX), and Lilly (Eli) (LLY) to gauge sector trends. Because Quest Diagnostics is part of the S&P 500, its performance can be influenced by broad market movements and investor rotation between sectors. Key factors to monitor include earnings reports, dividend policy updates, debt levels, and any changes in diagnostic testing demand.